Effect of Glucose-Insulin-Potassium on Hyperlactatemia in Patients Undergoing Valvular Heart Surgery
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Hyperlactatemia, occuring 10-20% in patients undergoing valvular heart surgery, is known to
be associated with hemodynamic instability, organ dysfunction and increased postoperative
morbidity and mortality. Glucose-Insulin-Potassium(GIK) has been constantly used as an
adjuvant therapy in patients with myocardial infarction or in the patients undergoing
valvular heart surgery to reduce the low cardiac output syndrome and mortality. GIK is known
to prevent excretion of lactate and to increase the extraction of lactate after reperfusion
with various mechanism. In addition, it is also known to decrease ischemic-reperfusion injury
of myocardium after CPB, to improve myocardial contractility, insulin resistance and
hyperglucemia. As a result, it brings hemodynamic stability and sufficient oxygen supply to
the tissue, which might reduce the incidence of hyperlactatemia after valvular heart surgery.